Marc G Berger

11PUBLICATIONS
25CO-AUTHORS
Predictive and prognostic markersMedical biotechnology diagnostics (incl. biosensors)Cancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Nov 07, 2024
Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.

F Huguet, A Guerci-Bresler, G Roth-Guepin

|Mar 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.

Francois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq

|Mar 03, 2024
Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.

Benjamin Lebecque, Joevin Besombes, Louis-Thomas Dannus

|Aug 30, 2022
Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.

Sandrine Saugues, Céline Lambert, Elisabeth Daguenet

|Jan 29, 2020
Semaphorin 7A: A novel marker of disease activity in Gaucher disease.

Mélanie Franco, Nelly Reihani, Lucie Dupuis

|Jul 05, 2019
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.

Marc G Berger, Bruno Pereira, Philippe Rousselot

Pageof 2

Frequent Collaborators

2 joint publications

Gabriel Etienne

2 joint publications

Delphine Réa

2 joint publications

Olivier Tournilhac

1 joint publications

E Cayssials